- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CERO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Fr | CERO THERAPEUTICS HOLDINGS, INC. - S-1, General form for registration of securities | - | SEC Filings | ||
| Di | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Announces Trading on OTCQB Market | 86 | GlobeNewswire (Europe) | Company's Shares Will Continue to Trade Under Ticker CERO SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB: CERO) ("CERo" or the "Company"),... ► Artikel lesen | |
| Di | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 19.11. | CERO THERAPEUTICS HOLDINGS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 17.11. | CERO THERAPEUTICS HOLDINGS, INC. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 1 | SEC Filings | ||
| 05.11. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Initiates Second Cohort of Phase 1 Clinical Trial of CER-1236 in AML with Patient Receiving Significant Increase in Dosing | 131 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif, Nov. 05, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTC PINK: CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company pursuing new... ► Artikel lesen | |
| 30.10. | CERo Therapeutics denied Nasdaq listing, seeks OTC markets | 23 | Seeking Alpha | ||
| 30.10. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Announces Receipt of Nasdaq Panel Determination | 632 | GlobeNewswire (Europe) | Trading of the Company's shares of common stock on Nasdaq will be suspended at the open of trading on October 31 CERo plans to appeal the Panel determination, seek trading of its shares on the OTC... ► Artikel lesen | |
| 21.10. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML | 229 | GlobeNewswire (Europe) | Company completes first tranche of a $7 million financing to increase cash runway and maintain Nasdaq compliance SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings... ► Artikel lesen | |
| 16.10. | Cero Therapeutics passt Kaufvertrag an und sichert sich 2,25 Mio. US-Dollar im ersten Closing | 4 | Investing.com Deutsch | ||
| 15.10. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025 | 2 | GlobeNewswire (USA) | ||
| 14.10. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 13.10. | CERo Therapeutics completes first cohort in AML clinical trial | 2 | Investing.com | ||
| 13.10. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML | 168 | GlobeNewswire (Europe) | Study's Dose Escalation Safety Committee approves initiation of Cohort 2 with fourth patient to receive increase in initial dose pending regulatory approval Company issues correction of recently published... ► Artikel lesen | |
| 10.10. | CERo Therapeutics open to takeover offers as it awaits key data - Axios | 9 | Investing.com | ||
| 10.10. | CERo Therapeutics signalisiert vor wichtigen Studiendaten Verkaufsbereitschaft | 2 | Investing.com Deutsch | ||
| 22.09. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.09. | CERo Therapeutics doses third patient in AML clinical trial | 1 | Investing.com | ||
| 22.09. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort | 216 | GlobeNewswire (Europe) | Third patient in the first cohort is now advancing through protocol-defined evaluations as Company anticipates additional results from second dosing of second patient in the cohort SOUTH SAN FRANCISCO... ► Artikel lesen | |
| 09.09. | CERo Therapeutics secures key patent protection for cancer therapy | 1 | Investing.com |
1 2 3 Weiter >>
58 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,021 | -1,77 % | PacBio Announces Third Quarter 2025 Financial Results | MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2025. Third quarter results: Q3 2025Q3 2024Revenue$38.4... ► Artikel lesen | |
| CARISMA THERAPEUTICS INC | 0,127 | -100,00 % | Carisma Therapeutics Inc.: Carisma Announces Delisting from Nasdaq and SEC Deregistration | PHILADELPHIA, Dec. 5, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (OTCID: CARM) (the "Company") today announced that its Board of Directors (the "Board") has... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 3,434 | +1,36 % | CytomX Therapeutics stock maintains Buy rating at H.C. Wainwright ahead of key data | ||
| CAPRICOR | 22,750 | -1,52 % | Capricor +727%: Biotech-Tipp schlägt heftig ein! | Capricor Therapeutics macht heute nicht nur mit positiven Studiennews auf sich aufmerksam: Dank eines gigantischen Multibagger-Kursfeuerwerks sorgt mein Biotech-Tipp aus dem Juli für glückselige Follower.... ► Artikel lesen | |
| CORMEDIX | 8,900 | -2,20 % | Can DefenCath Continue to Aid CorMedix's Long-Term Growth Ahead? | ||
| MINERVA NEUROSCIENCES | 3,100 | +12,32 % | Minerva Neurosciences, Inc: Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors | BURLINGTON, Mass., Nov. 19, 2025(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the appointment... ► Artikel lesen | |
| REPLIMUNE | 9,150 | 0,00 % | Replimune, Inc.: Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma | WOBURN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced... ► Artikel lesen | |
| VALERIO THERAPEUTICS | 0,154 | -4,35 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 24.07.2025 | Das Instrument C4X FR0010095596 VALERIO TH AC.PORT.EO-,01 EQUITY wird ex Kapitalmassnahme gehandelt am 24.07.2025 The instrument C4X FR0010095596 VALERIO TH AC.PORT.EO-,01 EQUITY is traded ex capital... ► Artikel lesen | |
| RANI THERAPEUTICS | 1,590 | +1,27 % | Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update | - Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics - - Completed $60.3 million oversubscribed private placement led by Samsara BioCapital... ► Artikel lesen | |
| IO BIOTECH | 0,697 | +2,74 % | IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights | Topline data from Phase 3 (IOB-013) clinical trial in advanced melanoma presented at ESMO; data highlights improvements in PFS achieved in overall population and across virtually all subgroups, although... ► Artikel lesen | |
| ALTO NEUROSCIENCE | 13,410 | +0,07 % | Alto Neuroscience, Inc.: Alto Neuroscience to Participate in Upcoming Investor Conferences | Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that... ► Artikel lesen | |
| OSR HOLDINGS | 0,735 | +6,00 % | Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target Following Major Licensing Agreement | New York, New York--(Newsfile Corp. - December 4, 2025) - Emerging Growth Research today issued a flash report on OSR Holdings, Inc. (NASDAQ: OSRH), reaffirming its Buy-Emerging rating and 12-month... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 247,99 | +30,54 % | Morning Market Movers: SMX, Praxis Precision Medicines, Polyrizon, Rubrik, Inc. See Big Swings | HONG KONG (dpa-AFX) - At 7:50 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| VERA THERAPEUTICS | 44,900 | +5,37 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| COGENT BIOSCIENCES | 38,770 | -1,37 % | Cogent Biosciences, Inc.: Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH) |
Das Unternehmen CERO THERAPEUTICS HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,095 Euro und damit +0,11 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CERO THERAPEUTICS HOLDINGS INC finden Sie auf Wallstreet Online.